Eli Lilly and Company (NEO:ZLLY)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.13T +7.8% |
| Revenue (ttm) | 89.37B +44.7% |
| Net Income | 28.30B +94.9% |
| EPS | 31.47 +96.0% |
| Shares Out | n/a |
| PE Ratio | 40.07 |
| Forward PE | 26.81 |
| Dividend | 0.02 (0.19%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 105 |
| Average Volume | 394 |
| Open | 9.85 |
| Previous Close | 9.65 |
| Day's Range | 9.85 - 9.87 |
| 52-Week Range | 9.50 - 12.05 |
| Beta | 0.50 |
| RSI | 40.78 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Eli Lilly to buy Kelonia Therapeutics in up to $7 billion cancer immunotherapy drug deal
CNBC's Angelica Peebles reports the latest news on pharmaceuticals.
Eli Lilly to acquire Kelonia in $7 billion cancer therapy push
Eli Lilly said on Monday it will acquire privately held Kelonia Therapeutics in a deal worth up to $7 billion, as the drugmaker deepens its presence in next-generation cancer treatments. The agreement...
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Eli Lilly said it has agreed to acquire biotech company Kelonia Therapeutics. Lilly will pay $3.25 billion upfront and up to $7 billion in total, the company said.
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted...
Eli Lilly Stock Falls as It Closes in on a $2 Billion Deal. Here's Why.
Eli Lilly's deal for Kelonia, which develops blood cancer therapies, could come as early as Monday.
Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says
Eli Lilly is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday.
Eli Lilly Nears Deal for Cancer Biotech
Deal for Kelonia Therapeutics could come as soon as Monday.
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390 prescriptions for its newly launched obesity pill in the U.S. for the week ended April 10.
Lilly CEO sees weight-loss drugs reaching about half of potential users at peak
Weight-loss drugs may eventually reach only about 50% of the overweight and obese people who could benefit from them due to complexities of healthcare systems and financial constraints, Eli Lilly CEO...
Lilly's new GLP-1 pill is off to a ‘robust' start
Lilly's new GLP-1 pill had 1,390 prescriptions in its first week on the market.
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral vision loss, leading to legal blindness by age 40–45.
Lilly confirms date and conference call for first-quarter 2026 financial results announcement
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that ...
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment
Eli Lilly's late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results.
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events In a pre-planned analysis, the ris...
LLY Stock To $2,000?
Can Eli Lilly (NYSE: LLY) stock surge 2x to $2,000 in the coming years? We believe that this is indeed a genuine possibility.
Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company
ROCKVILLE, Md.--(BUSINESS WIRE)--Linden Lake Labs (“L3”), an early-stage life sciences platform committed to advancing innovative therapies, today announced that its portfolio company, CrossBridge Bio...
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates
HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) today announced a defin...
Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm This trial predominantly enrolled a patient population previously treated with covalent ...
LLY v. NVO: Weighing Who's Winning the GLP-1 Industry
Scott Zari returns to the Watch List and offers the latest updates around the GLP-1 trade and the two companies leading it: Eli Lilly (LLY) and Novo Nordisk (NVO). He sees weight loss drug efficacy be...
Genetic variations linked to weight loss, side effects from GLP-1 drugs
Weight-loss responses to GLP-1 obesity drugs, and risks of side effects, may be linked to genetic variants, according to a study conducted by DNA-testing service 23AndMe.
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%.
Eli Lilly's Weight-Loss Pill Hits the Shelves. It's a Turning Point for the Stock.
The pharmaceutical's Foundayo drug takes on oral Wegovy, the popular treatment from Novo Nordisk.
Amazon to stock Lilly's new weight-loss pill at US kiosks, offer same-day delivery
Amazon.com said on Thursday its pharmacy unit will stock Eli Lilly's new weight-loss pill at kiosks located at some of the company's primary care clinics and offer same-day delivery of the drug.
Eli Lilly Weight-Loss Pill Becomes Available in U.S.
Eli Lilly's Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration's approval earlier this month, the company said.